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PROFILE OF UVEITIS IN A TERTIARY CARE CENTRE 
IN SOUTH INDIA 
 INTRODUCTION   
Inflammation of the uveal tract, the highly vascular middle layer of the eyeball (iris, 
ciliary body, choroid) is termed Uveitis. Anatomically uveitis is classified as anterior, 
intermediate, posterior or panuveitis, based on the anatomical parts of the uveal tract that is 
predominantly involved. Anterior uveitis is the most common type of uveitis. It accounts for 
50-92% of all uveitis cases in the West and 28-50% in the Asian countries. (1) 
Uveitis is further classified based on clinical features, laterality, presentation and 
etiology. Uveitis may present as an acute episode, recurrent episodes or remain a chronic entity 
requiring systemic medication and resulting in many vision threatening sequelae. Uveitis may 
present at any age and can affect both genders. 
According to the appearance of keratic precipitates on the endothelial surface of cornea, 
uveitis is classified as granulomatous or non-granulomatous. Laterality of involvement of the 
eye has been described as unilateral, bilateral or alternating (affecting one eye at a time and 
affecting both eyes alternately). (2) Etiologically, uveitis is classified as Infectious, Non-
infectious with a known systemic association or no known systemic association (idiopathic).(3) 
Infectious cause of uveitis can be viral, bacterial, spirochetal and parasite related inflammation 
and can present differently in immunocompetent and immunocompromised individuals.  
Common viruses that cause uveitis are herpes simplex (HSV), herpes zoster (HZV), 
cytomegalovirus (CMV), Epstein-Barr and human immunodeficiency virus (HIV). They are 
more common in immunocompromised patients. However, recent studies of isolated anterior 
uveitis have found HSV, VZV and CMV in the PCR of the aqueous samples. Herpes simplex 
is the commonest virus that causes uveitis. (4) Acquired CMV infection occurs in 30% patients 
with acquired immunodeficiency syndrome (AIDS), mostly as retinitis. 
 Tuberculosis (TB) is a major cause of uveitis in developing countries. It can present as 
acute, chronic or recurrent uveitis. Ocular manifestations may be caused by an active infection 
that invades the eye or by a delayed type IV hypersensitivity immunological reaction to various 
antigenic components of the mycobacteria, in the absence of the infectious agent. The clinical 
manifestations of ocular TB vary depending on mycobacterial virulence, host resistance to 
mycobacterium and the degree of tissue hypersensitivity to mycobacterial antigens. In India, 
where pulmonary tuberculosis is endemic, incidence of TB as a cause among patients 
presenting with uveitis is variable (0.6%-10.1%). The most common clinical presentations is 
posterior uveitis, followed by anterior uveitis, pan uveitis, and intermediate uveitis (5–7) 
Leprosy is caused by Mycobacterium leprae. About 60% of patients can develop ocular 
manifestation and half of them develop uveitis, mostly bilateral disease. The commonest form 
of anterior uveitis in leprosy is a chronic, low grade bilateral uveitis and usually becomes 
symptomatic late in the disease process only. Cataract, synechiae, glaucoma, iris atrophy, and 
ciliary body damage occurs insidiously causing loss of vision. As part of LOSOL study done 
in Karigiri with 301 patients with multibacillary (MB) leprosy, the age-adjusted prevalence of 
blindness and moderate to severe visual impairment was 2.8% and 5.2%, respectively. (8–10) 
Syphilitic uveitis can be included in the differential diagnosis of any form of uveitis 
due to its varied and unpredictable presentation. It can also occur at any stage of acquired 
syphilis. The prevalence of syphilitic uveitis (9%) is now increasing again in view of the HIV 
epidemic. (11) 
Toxoplasma related retinochoroiditis is caused by Toxoplasma gondii, an obligate 
intracellular parasite which causes progressive intraocular infection. This accounts for 30-55% 
of posterior uveitis and is a major cause of visual impairment. (12) 
 Non-infectious causes of uveitis are usually related to systemic connective tissue 
disorders. The ocular symptoms and signs could present either before, during or after the onset 
of systemic symptoms. The commonly encountered diseases are juvenile idiopathic arthritis, 
HLA–B27 related disease, Behcet’s disease, rheumatoid arthritis, systemic lupus 
erythematosus, Vogt-Koyanagi-Harada disease, sarcoidosis, Wegener’s granulomatosis, and 
other undifferentiated connective tissue disorders.  
HLA-B27 associated uveitis can be acute, anterior, non-granulomatous, recurrent and 
unilateral alternating. Age of onset is usually in the third decade which is a decade earlier than 
HLA-B27 negative anterior uveitis cases. HLA-B27 positivity rate between 41-56% has been 
reported in India. Ocular involvement occurs in 25% of patients with ankylosing spondylitis. 
(13) 
Vogt-Koyanagi-Harada (VKH) disease, a severe bilateral diffuse non-necrotizing 
granulomatous intraocular inflammation (posterior or panuveitis) associated with serous retinal 
detachments, disc edema, and vitritis, with eventual development of a sunset glow fundus, is 
an autoimmune inflammatory condition mediated by CD4+ T cells that target melanocytes in 
individuals susceptible to the disease. VKH was the most common cause of panuveitis in India, 
with a prevalence of 21.08 %.( 6) 
Ocular inflammation occurs in about 70% in patients with Behcet’s disease and tends 
to have a high risk of blindness. Disease tends to be more severe in men. Signs are always 
bilateral eventually. Relapsing or remitting acute onset panuveitis with retinal vasculitis and 
often spontaneous resolution even without treatment is the classical pattern of eye involvement. 
(14) 
 Sarcoid uveitis accounts for 3-10% of all cases of uveitis. Ocular inflammation occurs 
in 25-70% of sarcoid patients depending on ethnicity. Granulomatous anterior uveitis is the 
most common manifestation. (15–17) 
Childhood uveitis is most commonly associated with juvenile idiopathic arthritis (JIA), 
but can be observed in other autoimmune conditions like Behcet’s disease or sarcoidosis also. 
(18) 
Uveitis can have severe sequelae like posterior synechiae formation, cataract, cystoid 
macular edema, glaucoma, visual impairment. Upto 25% of irreversible blindness in India and 
other developing countries is due to uveitis. (19) 
Early diagnosis, appropriate local and systemic treatment and follow up would 
significantly reduce the morbidity associated with uveitis. Study of profile of uveitis in a 
population gives the spectrum of disease, allows for prioritizing relevant investigations for the 
region and can be used to develop management protocols and preventive measures as required 
in the community.  It helps to detect and monitor patterns of disease occurrence, changes over 
time and their presenting patterns. There is no paucity of literature on uveitis. However, there 
has not been a study on the profile of uveitis in patients seeking care for uveitis in South India 
in the last 5 years.  
    
 AIM AND OBJECTIVES 
Aim: 
To study the profile of uveitis in a tertiary care centre in South India 
 
 
Objectives: 
1. To study anatomic, demographic and etiologic profile of patients attending a uvea 
clinic in a tertiary hospital in South India. 
 
2. To study the characteristics, treatment response and complications of uveitis. 
 
  
 Review of Literature 
Uveitis is the inflammation affecting one or more of the three parts of the eye that make 
up Uvea: Iris, Ciliary Body and Choroid. Uveitis is broadly classified into Anterior, 
Intermediate, Posterior and Pan Uveitis based on the anatomical involvement of the eye. 
Uveitis can also involve adjacent structures like Sclera, Cornea, Retina, Vasculature and Optic 
nerve head. Uveitis includes a large spectrum of inflammatory diseases that can occur either as 
a co-manifestation of a non-infectious/autoimmune disorder, infection, malignancy or as a side 
effect of medications and toxins, or an idiopathic ocular inflammation (no known cause). 
Worldwide this disease is a sight threatening condition causing either transient or permanent 
visual impairment and ocular complications that may or may not respond to therapy. A delay 
in diagnosis and referral increases the risk that uveitis will result in irreversible damage to 
various ocular structures. (20) 
Epidemiology  
Worldwide uveitis has reported annual incidence between 17 and 52.4 per 1,00,000 
person years. The prevalence of uveitis is between 38 and 370 cases per 100,000 population, It 
is particularly prevalent in younger people; the mean age of uveitis patients at the onset of the 
disease is less than 40 years of age(21–23). Uveitis is the fourth most common cause of 
blindness among the working-age population in the developed world, it accounts for about 25% 
of blindness in developing countries. (1,2) 
Darrell et al. in 1962 demonstrated that only 14% of uveitis patients were considered 
elderly (>60 years of age). (22) However, this trend is changing especially in the developed 
countries in the last two decades. 
  Marwan R. et al in a systematic review found that the proportion of elderly (aging 60 
years or more) among the uveitis patients is more in the developed countries (18.6%) compared 
to the developing countries (7.2%). (25) 
 Idiopathic anterior uveitis is the most common form of uveitis in the community. (26)  
Infectious causes are common (30-60%) in the developing countries. Herpes and 
toxoplasmosis are the leading infectious causes of uveitis. Non-infectious uveitic conditions 
are generally more common in the developed world but the prevalence of infectious etiologies, 
including tuberculosis and syphilis are on the rise. 
The Pacific ocular inflammation study (27) showed that there was no difference in the 
incidence rate of uveitis between males and females. However, this study found that there was 
a higher prevalence of uveitis in females. The incidence and prevalence of uveitis were also 
found to increase with age.In a population study done in South India by Rathinam, et al 
(28)from 1995-1997, the prevalence of uveitis was found to be 450/100,000 and age-adjusted 
prevalence was 470/100,000. In this study, uveitis was found to be more common in males 
compared to females. (28) 
In a systematic literature review published in 2009 from Australia, (29) twenty two 
published studies on the epidemiology and etiological patterns of uveitis, from Australia, North 
and South America, Europe, Asia and Africa were analysed. They found that there were 
similarities as well as differences in the pattern of uveitis found in different geographic regions 
of the world, influenced by the geographical, environmental and genetic patterns. Anterior 
uveitis was found to be the commonest in Europe, Australia and most parts of the United States, 
followed by posterior uveitis. Idiopathic anterior uveitis was the commonest type of anterior 
uveitis, followed by uveitis associated with seronegative spondyloarthropathy, Fuchs 
heterochromic iridocyclitis, herpetic keratouveitis and sarcoidosis. Couto, et al (30) from 
 Argentina and Kotake, et al (31) found that panuveitis was more prevalent in Argentina and 
Japan. Idiopathic uveitis was the commonest type of panuveitis in Asian countries like Japan, 
Korea and Taiwan, followed by Behcet disease. (29) 
In a study done in a tertiary referral centre in south India, Biswas, et al (6) documented 
all new uveitis cases visiting their clinic over a two year period. Uveitis accounted for 1.5% of 
all new cases in their department. Out of 1273 uveitis cases, anterior uveitis (39.28%) was the 
commonest, followed by posterior uveitis (28.75%). Men (62.21%) were affected more than 
women. People in their forties (23.57%) constituted the commonest age group at presentation. 
Idiopathic, HLA-B27 negative cases accounted for most of the anterior uveitis (59.31%). 
In a retrospective chart analysis done in a uveitis clinic in a tertiary referral centre in 
North India, (5) the records of 1233 uveitis patients who were treated at the hospital from 1996-
2001, were analysed. Of the 1233 patients, 641 (51.98%) were males and 592 (48.01%) were 
females. The mean age was 34.4 years (range 1.5 to 75 years). Among the different types of 
uveitis, anterior uveitis was seen in 607 patients (49.23%), followed by posterior uveitis in 247 
patients (20.23%), intermediate uveitis in 198 patients (16.06%) and panuveitis in 181 patients 
(14.68%).  
Specific etiology was found in 602 patients only. The commonest specific etiology of 
uveitis in this study was infection, accounting for 29.73% (179 patients). Among the infective 
cases, tuberculosis was the commonest (125 patients, 69.8%), followed by toxoplasmosis (21 
patients, 11.7%). Non-infectious etiology of uveitis was found in 423 patients (10.06%), of 
which ankylosing spondylitis was the commonest cause (80 patients, 18.9%), followed by 
serpiginous choroidopathy (62 patients, 14.65%). 
 
 Classification and Nomenclature 
The most commonly used classification of uveitis is devised by SUN Working Group 
in 2005(Standardization of uveitis nomenclature). It is based on anatomic location of 
inflammation(Table 1), duration and activity For the purpose of research, the SUN working 
group (2005) has standardized definitions, grading of inflammation (Table 3 & 4) and outcome 
measures.(2) More recently in 2008,the International Uveitis Study Group(IUSG) designed a 
simplified classification of uveitis based on etiological criteria (Table 2).(3) 
Table 1: The SUN Working Group Anatomic Classification of Uveitis(2) 
Type Primary site of  inflammation Includes 
Anterior 
uveitis 
Anterior chamber Iritis,  
Iridocyclitis,  
Anterior cyclitis 
Intermediate 
uveitis 
Vitreous Pars planitis 
Posterior cyclitis 
Hyalitis 
Posterior 
uveitis 
Retina or choroid Focal, multifocal, or diffuse 
choroiditis 
Chorioretinitis,  Retinochoroiditis 
Retinitis Neuroretinitis 
Panuveitis Anterior chamber, Vitreous 
 and Retina or Choroid 
 
  
 
Table 2: International Uveitis Study Group (IUSG) 2008 (3) 
Infectious Bacterial  Viral Fungal Parasitic Others 
Non-
infectious 
Known systemic association Not known systemic association 
Masquerade Neoplastic Non-neoplastic 
 
Table 3: The SUN Working Group grading scheme for anterior chamber cells 
Grade Cells in Field(1mm x 1mm slit beam) 
0 <1 
0.5 1-5 
1 6-15 
2 16-25 
3 26-50 
4 >50 
 
 
 
 Table 4: The SUN Working Group grading scheme for anterior chamber flare  
Grade Description 
0 None 
1 Faint 
2 Moderate (iris and lens details clear) 
3 Marked (iris and lens details hazy) 
 
Duration and types of Uveitis (2) 
Active uveitis is characterised by circumcorneal congestion, fresh keratic precipitates, grade 
0.5+ or more cells in anterior chamber, (2) hypopyon, posterior synechiae, peripheral anterior 
synechiae on gonioscopy, vitreous haze and cells and active inflammatory lesions in the retina 
or choroid. 
Features of inactive uveitis include absence of circumcorneal congestion, pigmented keratic 
precipitates, grade 0 cells in anterior chamber,(1) pigments on anterior lens capsule, posterior 
synechiae, peripheral anterior synechiae on gonioscopy, and chorioretinal scars suggestive of 
old inflammatory lesions in the retina or choroid. 
Onset of uveitis can be described as sudden or insidious. 
Duration of uveitis is either limited, if it is 3 months or less in duration or persistent, if it is 
greater than 3 months in duration.  
Course of uveitis 
 Acute uveitis is defined as an episode of uveitis characterised by sudden onset and limited 
(less than or equal to three months) duration. 
 Recurrent uveitis is repeated episodes of uveitis separated by periods of inactivity with 
duration more than or equal to three months without treatment. 
Persistent uveitis with relapse in less than three months after discontinuing treatment is termed 
as chronic uveitis 
Remission- inactive disease for at least 3 months after discontinuation of treatment. 
Resistant to steroids - if there is no clinical improvement despite 2 weeks of treatment with                    
maximal dose. 
Resistant to immunosuppressives - if there is no clinical improvement despite 3 months of 
treatment. 
Inactive anterior uveitis is defined as rare anterior chamber cells or less. 
Improvement is defined as a 2 step decrease in the level of inflammation or a decrease to 
‘inactive’. 
Worsening is defined as a 2 step increase in the level of inflammation or an increase to 
maximum grade. 
Successful corticosteroid sparing is a reduction in the dose of prednisone to 10 mg per day 
or less while maintaining inactive uveitis. 
Granulomatous uveitis is characterised by large mutton fat keratic precipitates whereas    
Non-granulomatous uveitis consists of small keratic precipitates. 
  
Types of uveitis based on anatomic classification (2) 
Anterior Uveitis 
Definition: Anterior uveitis is the inflammation of the anterior chamber of the eye. It consists 
of iritis (inflammation of the iris), anterior cyclitis (inflammation of the anterior part of the 
ciliary body). (2) 
Prevalence: Anterior uveitis is the most common type of uveitis, which accounts for 50-92% 
of all uveitis cases in the West, and 28-50% in the Asian countries.(29) In a retrospective study 
from South India done over a two year period, out of 1273 cases of uveitis, anterior uveitis was 
the most common type, accounting for 500 cases (39.28%).(6)In a similar study done in North 
India, anterior uveitis was found in 607 cases, accounting for 49.23% of the total number of 
uveitis cases seen over a four year period.(5) In a retrospective study done on 308 uveitic 
patients in North Eastern India, anterior uveitis was again found to be the most common type 
(47.07%), followed by posterior(29.87%), intermediate(12.98%) and panuveitis (10.06%). 
Males outnumbered females in this study. The mean age at presentation was 32.5 years in males 
and 30.8 years in females, with a range of 2 to 61 years. (32) 
Clinical Features 
Symptoms: Patients present with redness, pain, watering, photophobia and blurred vision. 
Some patients may be asymptomatic. 
Signs: There may be circumcorneal congestion, keratic precipitates, pupillary miosis, posterior 
synechiae and dilated iris vessels. The major indicators of anterior uveitis are the presence of 
cells and flare in the anterior chamber. Gonioscopy may show peripheral anterior synechiae. 
Depending on the duration of the inflammation, intra-ocular pressure may be normal, high or 
 low. In the acute phase, intra-ocular pressure may be reduced due to ciliary shut down caused 
by the inflammatory process. Chronic uveitis with ciliary body atrophy may also present with 
low intra-ocular pressure and the eye may become pthisical. Uveitic eyes may have increased 
intra-ocular pressure due to trabeculitis, peripheral anterior synechiae or secondary steroid 
response. (33) 
Complications: Complications of anterior uveitis include cataract, glaucoma and cystoid 
macular edema. HLA-B27 positive patients tend to have more recurrent and severe episodes of 
anterior uveitis, and hence have been reported to have higher rate of complications. 
Etiology: Idiopathic anterior uveitis is the most common type, accounting for 38-88% of 
anterior uveitis.(19) The specific causes of anterior uveitis include seronegative 
spondyloarthropathies (ankylosing spondylitis, reactive arthritis, inflammatory bowel disease, 
psoriatic arthritis, undifferentiated arthritis), isolated HLA-B27 associated uveitis, Behcet 
disease, Fuchs heterochromic iridocyclitis, sarcoidosis, syphilis and Tuberculosis. 
 
Intermediate Uveitis 
Definition: The term ‘intermediate uveitis’ is used for the type of uveitis in which the vitreous 
is the major site of inflammation. 
The SUN working group’s international workshop (2005) states that the diagnosis of 
intermediate uveitis should not be changed with peripheral vascular sheathing and macular 
edema.  
Pars planitis: is an idiopathic Intermediate uveitis, when there is snowbank or snowball 
formation, in the absence of an associated infection or systemic disease. (2) 
 Prevalence: In the West, intermediate uveitis has been reported in 1.4-22% of uveitis 
patients.(2,7) Studies from India have found intermediate uveitis in 9.5-17.4% of uveitis 
patients.(34) The prevalence is estimated to be 5.9/100,000 and incidence, 1.4/100,000.(6) The 
prevalence of active intermediate uveitis was 0.25% in a South Indian study.(28) Though the 
disease affects patients in all age groups, intermediate uveitis is mostly seen in the third and 
fourth decade.(3,5,31) 
Clinical Features 
Symptoms: Patients with intermediate uveitis present with diminished vision and floaters, 
Onset of intermediate uveitis is generally insidious. There is usually no pain, photophobia or 
redness. (35)  
Signs: The anterior chamber may be quiet or there may be minimal cells and flare, or 
even a few keratic precipitates. The characteristic feature of active intermediate uveitis is 
vitreous haze. Vitreous snowballs are yellow-white inflammatory aggregates, and are found in 
mid vitreous and inferior periphery. Snowbanks are exudates on the pars plana. When present, 
they are usually found inferiorly, but may extend to 360 degrees of the retinal periphery. Snow 
banking is associated with a more severe form of disease, and hence warrants aggressive 
therapy. Retinal changes include sheathing of peripheral veins, cystoid macular edema and 
neovascularization. (35) 
Complications: Complications of intermediate uveitis are mainly due to its chronicity, and can 
lead to blindness. Chronic intermediate uveitis may lead to glaucoma, cataract, retinal 
complications like macular edema and epiretinal membrane formation. (36) 
 Etiology: Chang et al (29) in their systemic review found that 60-100% of intermediate uveitis 
found around the world was idiopathic. Specific diseases associated with intermediate uveitis 
are sarcoidosis, multiple sclerosis and Lyme disease. (35) 
 
 
Posterior uveitis 
Definition: The primary site of inflammation is the retina or choroid. It includes focal, 
multifocal or diffuse choroiditis, retinitis, retinochoroiditis, chorioretinitis and 
neuroretinitis.(2) 
Prevalence: Posterior uveitis accounts for 10.3-38.4% of the total number of uveitis cases. (6, 
37, 38)  
Clinical features 
Symptoms: Posterior uveitis may be insidious in onset, or have an acute presentation with 
floaters and blurred vision. 
Signs: Posterior uveitis may present with vitritis, choroiditis, retinitis or retinovasculitis. 
Complications: Decrease in visual acuity may occur due to different causes like the proximity 
to macula, sequelae of choroidal or retinal neovascularisation, epiretinal membrane formation 
or cystoid macular edema. (39)  
Etiology: Idiopathic uveitis comprised 3-78% of posterior uveitis in the systemic review by 
Chang ,et al.(29) The specific etiology of posterior uveitis are infective causes like 
toxoplasmosis, toxocariasis, tuberculosis, syphilis, bartonellosis, viral infections like Herpes 
 simplex, Varicella zoster, Cytomegalovirus and HIV. The non-infectious types of posterior 
uveitis include the white dot syndromes like Acute posterior multifocal placoid pigment 
epitheliopathy(APMPPE), Multiple evanescent white dot syndrome(MEWDS), Geographic 
helicoid peripapillary choroidopathy(GHPC),  Multifocal choroiditis(MFC), Punctate inner 
choroidopathy(PIC), Birdshot choroidopathy, Subretinal fibrosis and uveitis syndrome(SFU), 
Diffuse unilateral subacute neuroretinitis (DUSN) and Retinal pigment epithelitis (Krill’s 
disease. (40) 
Panuveitis 
Definition: The term ‘panuveitis’ refers to uveitis in which there is no predominant site of 
inflammation, but inflammation is seen in the anterior chamber, vitreous and retina and or 
choroid. (2) 
Prevalence: Panuveitis accounts for 14.5-36.2% of the total number of uveitis patients in 
various studies. (6, 37, 38) 
Clinical features 
Symptoms: Patients present with pain, blurring of vision, floaters and redness of the eye. 
Signs: Severe anterior chamber reaction, vitritis, choroiditis, retinitis, retinal vasculitis and 
optic disc edema may be seen in panuveitis. 
Complications: Panuveitis is found to have the worst outcome among all types of uveitis. 
Panuveitis can also lead to retinal ischemia, neovascularisation, secondary optic atrophy, 
epiretinal membrane, complicated cataract and uveitic glaucoma. (39) 
Etiology: 3-92% of pan uveitis seen world-wide is idiopathic. (29) 51.3% of pan uveitis seen 
in India by Biswas, et al (6) was idiopathic. Vogt-Koyanagi-Harada(VKH) disease(21.08%) 
 and sarcoidosis(11.35%) have been reported to be the most common specific causes of 
panuveitis in India.(34) Das et al(41) have reported that the most common etiology of pan 
uveitis in North-Eastern India was VKH disease(45.06%), followed by sarcoidosis(29.03%). 
Other reported specific causes are sarcoidosis, syphilis, Behcet disease and sympathetic 
ophthalmia. 
Uveitis due to infection 
Tubercular Uveitis 
Tuberculosis is a major cause of uveitis in underdeveloped countries. It is mostly seen 
in young adults though no age is immune. It is seen slightly more among women than men. It 
is a unilateral disease but bilaterality is seen in miliary tuberculosis. It can present as acute, 
chronic or recurrent uveitis although chronic is more common. Less than 1% patients with 
pulmonary or extrapulmonary tuberculosis suffer from uveal tuberculosis but the incidence of 
frank tuberculosis in patients with uveal tuberculosis is rare. Iridocyclitis that does not respond 
well to local steroids and cycloplegics without joint involvement, the first infective condition 
that should arouse suspicion is tuberculosis. 
Ocular manifestations may be caused by an active infection that invades the eye or by 
a delayed type IV hypersensitivity immunological reaction to various antigenic components of 
the mycobacteria, in the absence of the infectious agent. Most patients with ocular TB have no 
history of pulmonary or systemic disease. The clinical manifestations of ocular TB vary 
depending on mycobacterial virulence, host resistance to mycobacterium and the degree of 
tissue hypersensitivity to mycobacterial antigens. Tuberculosis is primarily an airborne 
(droplet) infection. The infection causes disease within the first few years after exposure in 
about 5% of patients. In another 5% the disease may develop several years later as a result of 
 altered host immunity.  About 90% of infected persons never develop any clinical disease and 
remains asymptomatic throughout their lifetime. A positive PPD test can identify these infected 
patients, (42–44) 
In India, where pulmonary tuberculosis is endemic, Incidence of TB as a cause among 
patients presenting with uveitis is variable(0.6%-10.1%).(5,6) In a study involving 1,005 
patients with active pulmonary and extrapulmonary tuberculosis from South India, Biswas et 
al reported an ocular morbidity of 1.39%. (7) .In 2003, study done at a tertiary referral centre 
in north India, Singh et al found that out of 179 patients with infectious aetiological diagnosis, 
the commonest was tuberculosis (125 patients; 69.8%). Tuberculosis was also the most 
common cause of panuveitis (26.0% of panuveitis patients). (5) The increasing application of 
PCR from intraocular fluids to diagnose tuberculous uveitis has led to an increase number of 
patients being labelled with tubercular etiology. (45) The most common clinical presentations 
are posterior uveitis, followed by anterior uveitis, pan uveitis, and intermediate uveitis. 
Uveitis in Leprosy 
The disease is caused by Mycobacterium leprae. About 60% of patients with leprosy 
develop ocular manifestation and half of them develop uveitis, mostly bilateral. It takes 10-15 
years for ocular involvement to be evident. It affects both the sexes equally in all ages. 
Incidence in children is less. Uveitis is more common in lepromatous leprosy. The anterior 
segment is more commonly and severely affected than the posterior segment. It can be acute 
exudative iridocyclitis, chronic iridocyclitis or solitary leproma. The acute exudative 
iridocyclitis is seen as part of type II lepra reaction. Leprotic pearls is seen in chronic 
iridocyclitis. These are small white nodules spread all over the iris and sometimes on posterior 
synechiae. 
 Syphilitic Uveitis 
The disease is caused by Treponema pallidum. Uveitis can occur in both congenital and 
acquired syphilis. The incidence of syphilitic uveitis is now increasing again in view of the 
HIV epidemic. In congenital syphilis, uveitis can be either associated with interstitial keratitis 
where the disease starts in the uvea and spreads to the cornea or without the same. It can be 
associated with diffuse chorioretinitis that leaves a fundus picture of pepper and salt appearance 
without night blindness. Uveitis in acquired syphilis is seen in late secondary stage or in tertiary 
stage, between 3-12 months after primary infection. Anterior segment is more commonly 
involved than the posterior segment. The lesions are predominantly granulomatous. The 
iridocyclitis can be acute or gummatous iridocyclitis. The disease does not respond to 
cycloplegic and steroids. (46–49) 
Viral Uveitis 
Common viruses that cause uveitis are herpes simplex, herpes zoster, cytomegalovirus, 
Epstein-Barr and HIV. It is more common in immunocompromised patients. Herpes simplex 
is the commonest virus that causes uveitis. 
Herpes Simplex Uveitis 
Herpes simplex uveitis is mostly recurrent, never primary. The duration of latent period 
may vary from months to years. Keratouveitis is more commonly seen than iridocyclitis with 
herpes simplex infection. The herpetic iridocyclitis is an acute, painful condition with 
diminished vision. There is marked circumciliary congestion with a heavy aqueous flare, 
hyphaema and large KPs. (50) 
Cytomegalovirus Uveitis 
 CMV infection is seen only in posterior uvea as either chorioretinitis or retinitis. About 
80% of adults over 35 years of age are seropositive for CMV infection that they had suffered 
either as congenital or as acquired asymptomatic disease. 1% of live births may have systemic 
CMV infection, out of which only one tenth will show evidence of the disease in infancy and 
childhood. About 50% of them will develop symptomatic ocular lesion, sensory neural 
deafness and mental retardation. Acquired CMV infection occurs in 30% patients with AIDS, 
mostly as retinitis. The lesions are bilateral, cotton wool spots, superficial haemorrhages with 
periphlebitis, venous sheathing and vitreous haze. CMV retinitis may be the first presenting 
sign of AIDS in a patient who has CD4 cell count less than 100 millimetre cube.  
HIV manifestations   
Posterior segment lesions are more common in AIDS than anterior segment 
manifestations and can lead to severe ocular morbidity, often irreversible.  
Cytomegalovirus is the most common infectious agent affecting the posterior segment. 
It is seen in 15-40% of the patients. If the infection does not involve the posterior pole, patient 
may be asymptomatic or present with decreased vision. Symptom of floaters could be an early 
indication of the disease, although vitritis occurs occasionally only. Well established CMV 
retinitis is easily recognised by ‘pizza pie’ appearance. 6% of cases with CMV retinitis can 
have frosted branch angitis. Retinal detachment is seen in healed stage in 30% of cases. The 
infection can occur 3-5 years after the diagnosis of AIDS and usually develops when CD4 
counts are less than 50 cells per millimetre cube.  
Uveitis can be the first presentation of systemic syphilis both in immunocompetent and 
immunocompromised individuals on HAART. Syphilis presents with vitritis or panuveitis. 
 Ocular syphilis can cause significant inflammation inspite of low CD4 counts. Diagnosis can 
be challenging in some (38%) HIV positive patients but remains sero-negative despite active 
syphilitic disease. 85% HIV patients with ophthalmic syphilis have coexisting neurosyphilis. 
Isolated episcleritis and scleritis are uncommon but are usually features of secondary and late 
syphilis. 
Cryptococcus neoformans is the most common fungal infective agent in AIDS. It 
causes chronic chorioretinitis.  
Candidial endophthalmitis is uncommon and is usually present in either highly drug 
abusers or having indwelling catheters. 
Ocular tuberculosis can present as anterior uveitis, choroiditis, choroidal granulomas, 
chorioretinitis and panuveitis. Choroidal tuberculosis is common in HIV infection and it has 
no correlation with CD4 counts. (39) Ocular TB has an aggressive course in AIDS patients 
which might not resolve with ATT even when there is improvement in systemic TB. Initiation 
of HAART before anti-TB therapy can lead to florid inflammation and paradoxical worsening 
due to immune reconstitution inflammatory syndrome (IRIS). Regular ocular screening of 
ocular TB is imperative in all cases of HIV in India inspite of good CD4 counts and regular 
HAART. 
Toxoplasma retinochoroiditis – Toxoplasma gondii protozoan affects 10% of patients 
with AIDS but accounts for only 1% of AIDS related retinal infection. It is usually caused by 
newly acquired infection and can cause progressive intraocular infection, panophthalmitis and 
orbital cellulitis in AIDS. CNS lesions are seen in 25-50% patients with ocular toxoplasmosis. 
 
 Parasitic Uveitis 
Toxoplasmosis 
Toxoplasmosis is caused by Toxoplasmosis gondii, a protozoan. It is estimated to infest 
10% of adults in northern temperate countries and more than half of adults in tropical countries. 
A critical mode of human infection is transplacental hematogenous spread to the fetus in a 
pregnant woman with active toxoplasmosis. In congenital toxoplasmosis, retinochoroiditis 
occurs in over 75%, leaving scars. Acquired toxoplasmosis in immunocompetent adults is 
subclinical in 80-90%. Toxoplasmosis constitutes 20-60% of all posterior uveitis. Reactivation 
at previously inactive cyst-containing scars is he rule in the immunocompetent. ‘Spill over’ 
anterior uveitis may be granulomatous and resembles Fuchs uveitis syndrome with elevated 
IOP. Vitritis may be severe and impair fundus visualization. White retinal inflammatory nidus 
is viewed as ‘Headlight in the fog’. Vasculitis is more commonly venous. Toxoplasmosis 
causes permanently reduced vision in 25% of eyes. Toxoplasma IgG antibodies are detectable 
in the serum within 1-2 weeks of infection. PCR testing of intraocular fluid is variably sensitive 
(16-67%) but highly specific. Ocular fluid antibody assessment by Goldmann-Witmer  
Toxocariasis 
Toxocariasis is caused by an intestinal ascarid (roundworm) Toxocara canis or 
Toxocara cati. Ocular toxocariasis is associated with a lower parasitic load. It is typically 
unilateral and in two-thirds causes some degree of permanent visual impairment. 
 
 
 Non Infectious Uveitis with known systemic association 
HLA-B27 Associated Uveitis 
HLA-B27 associated uveitis is described as acute, anterior, non-granulomatous, 
recurrent and unilateral alternating. Males are affected between 1.5 to 2.5 times more than 
females. HLA-B27 negative anterior uveitis does not show a gender difference. (13,33, 51–57)  
HLA-B27 and the spectrum of associated inflammatory diseases have one of the 
strongest Human Leukocyte Antigen and disease association known till date (21, 58–60). HLA-
B27 accounts for 18-32% of all cases of anterior uveitis in western countries. (37,38,61,62)         
In a study done in North India, the HLA-B27 positivity rate was 56.2% among uveitis patients 
and 3% in control samples.(63) The age of onset occurs between 20 and 40 years, whereas the 
onset of HLA-B27 negative anterior uveitis usually occurs a decade later.(13,21,33,51,56,57) 
HLA-B27 positive anterior uveitis can occur in isolation but they may go on to develop 
spondyloarthropathy on later follow ups. Linssen, et al (57) found that after a follow up of 9 
years, 12% of patients with isolated HLA-B27 positive anterior uveitis in their series, 
subsequently developed spondyloarthropathy.  
HLA-B27 associated anterior uveitis is known to cause severe sequelae like posterior 
synechiae formation, cataract, cystoid macular edema, glaucoma and worse visual acuity 
compared to other forms of anterior uveitis Based on studies done in tertiary referral centres in 
the West, over 65% suffered from ocular complications of uveitis(57,64) Most common ocular 
complications where Posterior synechiae (13 -91%)  Cataract (7-28%)  
Other complications include ocular hypertension, secondary glaucoma and the 
development of chronic anterior uveitis. (13,33,51,56,57,64) The complications related to 
HLA-B27 are usually confined to the anterior segment of the eye. However, posterior segment 
 complications (17-25%) are also reported.  Around (6-13%) patients with HLA-B27 can 
develop Cystoid macular edema (34,51,65) papilitis and severe vitritis have also reported. (64) 
Posterior segment complications may be sight threatening, thus requiring aggressive 
medical and surgical management. In the series by Rodriguez, et al (34) 32% of the HLA-B27 
associated anterior uveitis patients with posterior segment complications required systemic 
immunosuppressive therapy and in the series by Bayen, et al (66) 17% of the patients required 
pars plana vitrectomy for control of inflammation and preservation of vision. 
HLA type Associated disease 
HLA-B27 Recurrent acute anterior uveitis 
HLA-A29 Birdshot retinochoroidopathy 
HLA-B51 and HLA-B5 Behcet syndrome 
HLA-B7 and HLA-DR2 Ocular histoplasmosis syndrome 
HLA-DR4 Sympathetic ophthalmitis 
HLA-DR4 Vogt-Koyanagi-Harada syndrome 
 
 
 
 
 Ankylosing Spondylitis 
Ankylosing spondylitis is a chronic inflammatory arthritis that primarily affects the 
spine and sacroiliac joints. Ocular involvement occurs in 25% of patients with ankylosing 
spondylitis. (60)  Anterior uveitis is the most common manifestation. It is typically unilateral, 
but can be bilateral or alternating. Both eyes are involved in 80% patients, but they are rarely 
inflamed simultaneously Recurrence of the ocular inflammation may occur as frequently as 
every 2-3 weeks. (67) Anterior uveitis associated with ankylosing spondylitis usually presents 
as a unilateral, acute iritis with pain, photophobia and redness. 
Reactive Arthritis 
Reactive arthritis may occur after dysentery caused by Gram-negative bacteria like 
Shigella, Salmonella, Campylobacter. (67) Most patients have signs 2-4 weeks after the onset 
of dysentery, but the full syndrome may take years to develop. (68) It has a male preponderance 
and onset of symptoms is generally between 18-40 years. Conjunctivitis is the most common 
ocular finding in patients with reactive arthritis, and occurs in 30-60% patients. It is usually 
mild and bilateral. Anterior uveitis occurs in 3-12% patients. It is usually non-granulomatous 
and may have mild cellular reaction, hypopyon, peripheral anterior synechiae and trabeculitis. 
Patients can also present with keratitis, scleritis and episcleritis. Scleritis is usually in the form 
of diffuse anterior scleritis and never progresses to necrotizing scleritis. 
 
 
 
 Psoriatic Arthritis (69) 
Uveitis occurs predominantly in patients who develop arthropathy. About 20% of 
patients with psoriasis develop psoriatic arthropathy and about 20% of these patients develop 
uveitis, sacroiliitis and ascending spine disease (F76). Anterior uveitis is similar to that found 
in ankylosing spondylitis and reactive arthritis. 
Undifferentiated Spondyloarthritis 
A diagnosis of undifferentiated spondyloarthropathy is made when the patient fulfils 
the criteria for spondyloarthropathy without evidence suggesting a more specific disorder. The 
disease can either remain the same for many years or can progress into well-defined subsets of 
spondyloarthropathy. Majority of the patients (59-68%) may progress to ankylosing spondylitis 
within 3-11 years. (70–72)  
Vogt-Koyanagi-Harada (VKH) Disease  
VKH is an idiopathic multisystem autoimmune disease with Granulomatous 
inflammation of melanocyte containing tissues such as the skin, uvea, ear and meninges. VKH 
predominantly affects Hispanic, Japanese and pigmented individuals. It is associated with 
HLA-DR1 and HLA-DR4.  
Vogt-Koyanagi-Harada disease uveitis is a severe bilateral diffuse non-necrotizing 
granulomatous intraocular inflammation (posterior or panuveitis) associated with serous retinal 
detachments, disk edema, and vitritis, with eventual development of a sunset glow fundus, is 
an autoimmune inflammatory condition mediated by CD4+ T cells that target melanocytes in 
individuals susceptible to the disease.  
 The trigger that induces altered tolerance to melanocytes is still not known. The 
tyrosinase peptide antigen is the target of autoimmunity by T lymphocytes on recognition of 
HLA DRB1*0405 expression by the melanocytes. Infections may play a role in initiating the 
autoimmune process. The lack of prior inciting trauma differentiates it from sympathetic 
ophthalmia. (73–76) 
Vogt-Koyanagi-Harada disease presents clinically in 4 different phases: prodromal, 
uveitic, convalescent, and recurrent, with extraocular manifestations including headache, 
meningismus, tinnitus, hearing loss, poliosis, and vitiligo, to varying degrees. (77,78) 
The mainstay of treatment has been corticosteroids and, more recently, steroid-sparing 
immunomodulators for long-term control. 
Epidemiology and geographic distribution 
The prevalence of VKH varies in different populations in the world, being more 
common in Asia, Latin America, and the Middle East with prevalence rates ranging from 4.4% 
to 21%.(79)  VKH is not common in the United States and makes up only about 3% to 4% of 
referrals to tertiary care centres.(80)  
The patients diagnosed with VKH were predominantly female (69-77%), Hispanic 
(54%-78%) and  a mean age of 33.5 years (range 7 to78 years) VKH appears to be more 
common in pigmented individuals and is relatively rare in whites.(79,81,82) VKH was the most 
common cause of panuveitis in India, with a prevalence of 21.08%. (6) 
Vogt-Koyanagi-Harada disease (VKH) in children 
Martin et al studied new cases of uveitis in South India and noted 1.2% of patients with 
a diagnosis of VKH of which 8.2% were children. Age of presentation was 8 to 16 years, and 
 median age was 13.5 years. Most children ultimately did well, with a final vision of better than 
6/12 in 75%. 
Hamade IH et al, in a study done in Saudi Arabia, the prevalence of VKH in children 
younger than 16 years of age was as high as 16%, behind acute anterior nongranulomatous 
uveitis and intermediate uveitis. This study found that 54% of children with VKH had vision 
better than or equal to 6/12. But had the highest rate of complications; that is, glaucoma in 
50%, papilitis in 53%, epiretinal membrane in 16%, and retinal detachment in 4%. Children 
were at risk of amblyopia secondary to VKH. (83,84) Patients over age 60 years (age range 60-
86 years) were found to have a lower prevalence of VKH  compared to younger patients.  
Patients above age 65 years had a higher incidence of optic disk hyperemia, choroidal 
detachment, and cataract compared to younger patients. They were also more likely to need a 
higher dose of corticosteroids and often maintained good vision despite low-grade smoldering 
inflammation.(85,86) 
The prodromal phase may present a viral infection and lasts for few days to few weeks. 
Clinical manifestations are predominantly extraocular including headache (82%), 
meningismus (55%), fever (18%), nausea (9%), vertigo (9%), orbital pain, and auditory 
disturbances. Cerebrospinal fluid may show pleocytosis in more than 80% of patients. (74) 
Acute uveitic phase sudden onset, bilateral granulomatous uveitis is seen in upto 70% of 
patients presents with pockets of subretinal fluid, hyperemia of the optic nerve head and 
choroidal thickening causing blurring of vision and conjunctival injection. Anterior segment 
shows granulomatous reaction with the presence of mutton fat keratic precipitates. Forster et 
al reported that an increase in IOP is seen in up to 54% of patients and 38% of patients requiring 
medical or surgical intervention.    
 In Convalescent phase Depigmentation of the choroid, sunset glow fundus, vitiligo, and 
poliosis occurs. , progression occurs in 28%–62% of patients who present with acute VKHD.  
Chronic recurrent phase is characterized by exacerbations of granulomatous anterior uveitis 
that is usually resistant to systemic steroid therapy and with later involvement of the 
choriocapillaris. It  usually develops 6 to 9 months after initial presentation and is also marked 
by complications- retinal pigment epithelium proliferation, subretinal fibrosis(6%), subretinal 
neovascular membranes(3%-11%), posterior subcapsular cataract (15%-45%), posterior 
synechiae (23.4%), band keratopathy(5.2%) open-angle glaucoma (27%-33%), and, 
occasionally, angle-closure glaucoma. Forster et al found that recurrent inflammation was a 
significant risk factor for poor visual outcome. (87–89) 
Extraocular manifestations 
Neurologic signs, occur more commonly during the prodromal phase. 18-50% of 
patients have some form of sensory hearing loss, mostly at higher frequencies of 4, 6, and 8 
kHz.154, Tinnitus is present in 42% of the patients. (90,91) 
Integumentary changes associated with VKH develops in about 30% of patients.(92) It 
occurs in the convalescent phase, when depigmentation of the choroid occurs, the eyebrows, 
eyelashes, hair, and skin also lose pigment, resulting in poliosis and vitiligo.(93,94) 
The initial treatment is with high-dose corticosteroids, then steroid-sparing therapy, 
Despite early treatment, progression to the chronic recurrent phase may occur in up to 79% of 
the total cases who presented with acute VKHD.4 VKH is a severe inflammatory disease, but 
prompt and aggressive treatment, may lead to better visual outcomes 6/ 6-6/18 .(95–97) 
 
 Modified diagnostic criteria for Vogt-Koyanagi-Harada syndrome 
1.Absence of a history of penetrating ocular trauma 
2.Absence of other ocular entities 
3.Bilateral uveitis 
4.Neurological and auditory manifestations 
5.Integumentary findings, not preceding onset of central nervous system or ocular disease 
such as alopecia, poliosis and vitiligo. 
Sympathetic Ophthalmitis 
 Sympathetic ophthalmitis is a bilateral granulomatous panuveitis occurring after 
penetrating trauma. Less frequently the condition occurs following intraocular surgery. 
Presentation in trauma induced cases is between 2 weeks and 3 months after initial injury in 
65%. The incidence is probably 0.2%-0.5% after injury and 0.01% following intraocular 
surgery. 
Sarcoidosis 
Sarcoidosis is a chronic multisystem disorder of unknown cause, manifesting with non-
caseating granulomatous inflammatory foci. It has an incidence rate of 6-10 per 1,00,000. It 
affects lungs, lymph nodes, skin, liver, eye, heart and muscles.  Ocular inflammation occurs in 
25-70% of sarcoid patients depending on ethnicity. Granulomatous anterior uveitis is the most 
common manifestation. Women are affected in 41% of cases in India.  
The ACCESS study a multicentre study from 10 specialist centres across the United 
States. Patients usually present between 20 and 40 years of age .Women were more likely to 
 be affected. In clinical manifestations; women tended more to ocular and neurological 
involvement, whereas men had a higher risk of hypercalcemia. (98,99) 
In United Kingdom, 5.9% of patients have an affected relative, (100) the relative risk 
of sarcoidosis for family members in the United States is 4.7, siblings being at highest risk 5.8. 
There are differences in disease prevalence between countries. In Japan this is as low as 
3.7:100,000, compared to Finland where it is as high as 28.2:100,000. (101) 
Sarcoid uveitis accounts for 3-10% of all cases of uveitis. The International workshop 
on Ocular Sarcoidosis (IWOS), 2009 has set up the criteria for diagnosis of intraocular 
sarcoidosis. (16) 
Common clinical manifestations Systemic sarcoidosis dyspnoea, dry cough, or wheeze 
(31-50%). bilateral hilar lymphadenopathy (79%-95%), skin involvement (25%) subclinical 
hepatic involvement (75%), clinically significant Cardiac sarcoidosis (<5%), Neurological 
involvement (5–26%) of these facial or optic neuropathies (50–75%), (15,102,103) 
The onset of Ocular Sarcoidosis is usually insidious and has a chronic course patients 
presents with blurred vision, floaters, redness, or discomfort, In biopsy proven cases ocular 
features include granulomatous uveitis, iris nodules (52%). 
Trabecular meshwork nodules and/or tent-shaped PAS (81%), Ocular hypertension 
(34%), Snowball/string of pearls vitreous opacities (69%). Multiple peripheral chorioretinal 
lesions active and/or atrophic(76%), Nodular and/or segmental periphlebitis (± candlewax 
drippings) and/or retinal macroaneurysms (45%), Optic disc nodule(s)/granuloma(s) or solitary 
choroidal nodule(6%), Bilaterality(98%).Common complications of chronic ocular sarcoidosis 
are Cataract, Glaucoma, and Cystoid macular edema(16,17,67,104) 
 Behcet disease 
Behcet disease is an idiopathic, multisystem syndrome characterised by recurrent 
aphthous oral ulcers, genital ulceration and uveitis. Vasculitis is a key pathogenetic component 
and may involve small, medium and large veins and arteries. It is strongly associated with 
HLA-B51. The peak age of onset is the third decade. The International Study Group for Behcet 
disease (ISGBD), 1990 established criteria for diagnosis of Behcet disease. 
Ocular inflammation occurs in about 70% and tends to be more severe in men. Signs 
are always bilateral eventually. Relapsing or remitting acute onset panuveitis with retinal 
vasculitis and often spontaneous resolution even without treatment is the classical pattern of 
eye involvement. Retinal vascular disease (vasculitis and occlusion) is the main cause of visual 
impairment.  
Childhood Uveitis 
Non-infectious paediatric uveitis can lead to ocular complications and vision loss. It is 
most often associated with juvenile idiopathic arthritis (JIA), but can be observed in other 
autoimmune conditions like Behcet’s disease or sarcoidosis. Idiopathic uveitis is common as 
JIA-associated uveitis (JIA-U). Anterior uveitis is the most common manifestation. Ocular 
complications are reported in up to 50% of children. Moderate visual impairment affects 25-
40% children and severe visual impairment in upto 25% children. Angeles-Han reported that 
the odds of developing juvenile idiopathic arthritis associated uveitis increases nine fold when 
the subjects carried both HLA-DRB1*11 and *13. Association between autoimmune chronic 
uveitis in children with the presence of NOD2/CARD15 gene was reported by Marrani, et al. 
 Risk factors for sight-threatening complications in paediatric non-infectious uveitis 
include short duration between arthritis and uveitis diagnoses, young age at uveitis onset, male 
gender, uveitis diagnosed prior to arthritis, and the presence of vision loss or complications at 
first ophthalmology exam. (105,106) 
Juvenile idiopathic arthritis 
Juvenile idiopathic arthritis (JIA) is the most common group of systemic diseases 
causing uveitis in childhood. It has a prevalence of 10 per 100 000 persons. It occurs more in 
girls (75–80%) and 70–90% of them are antinuclear antibodies positive JIA often has a severe 
inflammatory course, and endangers vision.  
Approximately 10–20% of children with JIA are at risk for uveitis. Those with positive 
antinuclear antibodies (ANA), are young at arthritis diagnosis (≤ 6 years old), have 
oligoarticular or polyarticular RF negative JIA, and early in their disease course (≤ 4 years) are 
considered high risk. The intraocular inflammation is mostly diagnosed between the 4th and 
6th years of life shortly before or within four to five months after arthritis onset, in some 75% 
within a year, in 90% within four years, and in only 3–5% before or five or more years after 
the onset of JIA. In 75% of children the inflammation affects both eyes, simultaneously or 
within a few months of each other. Current screening guidelines recommend monitoring these 
children every 3–4 months. (105,106) 
The diversity of etiology in uveitis occurs due the influence of factors like geographic 
location, regional differences, climatic changes, occupation and socioeconomic profile. (107) 
Epidemiology of uveitis varies in different parts of our country. In a study from a referral centre 
in south India, the prevalence of uveitis was reported to be 1.5% of new cases presenting to the 
 centre. Anterior uveitis was the most common diagnosis, males were more affected, age group 
was 40 years and the commonest etiology among the anterior uveitis was idiopathic 
inflammation.(6) In another study, leptospiral, tuberculous and herpetic disease was identified 
in patients with uveitis as most common identifiable infectious etiology. Parasitic uveitis was 
common in children less than 16 years of age and herpetic etiology the most common in those 
above 60 years of age. (107) In another study from north India, anterior uveitis was the 
commonest presentation, males were more affected. The 2 commonest infectious etiology 
detected were tuberculosis followed by toxoplasmosis. Among the non-infectious causes 
ankylosing spondylitis was the most common. (5) 
In our study we would like to describe the anatomic, demographic and etiologic profile 
of patients attending our uveitis clinic and compare it to the patterns of uveitis globally and 
from different parts of our country. 
 
 
 
 
 
  
 Methodology 
This was a hospital-based cross-sectional study. The study was conducted over a 
twelve-month period, from November 2015 to November 2016, after receiving the approval 
of the Institutional Review Board (IRB Min No. 10338). 
Patients who attended the Uvea Clinic of the Department of Ophthalmology, Christian 
Medical College, Vellore with a presumed or proven diagnosis of uveitis were included in the 
study. A detailed history was elicited from all patients. Every patient in the study had a 
complete ophthalmological evaluation to look for evidence of past or present uveitis. All 
patients were examined using a slit lamp biomicroscope. The diagnosis of uveitis was made 
based on established international diagnostic criteria. (3,16,36,74,108–110) The diagnosis of 
uveitis was confirmed by consultant ophthalmologists in the department, with more than ten 
years of experience in the specialty. Appropriate investigations were done when indicated 
Systemic diagnosis were confirmed (or ruled out) through consultation with concerned 
specialists (adult/paediatric Rheumatologist, adult/paediatric Infectious disease specialist).  
 
Inclusion Criteria 
Patients with diagnosis of anterior/ intermediate/ posterior/ pan uveitis and scleritis. 
Exclusion criteria 
1. Uveitis in the same eye within 3 months of trauma /surgery or any intraocular       
procedures. 
2. Any other disease which may be associated with or masquerade as uveitis. 
 
 
 
 
 Data collection 
 Data collection was done using a ‘Clinical research form’ (Appendix II). Clinical data, 
investigations and treatment details were recorded. Form included details pertaining to  
 Age, Gender, Occupation, Residence,  
 Family history pertaining to systemic illness (Connective tissue/ autoimmune/ 
infection)    
 Medical history of Systemic illness, Exposure to infection/animals                              
 Ocular history- Number of episodes, Laterality and ocular symptoms of Initial episode 
of Uveitis 
 Past treatment history, Compliance, Response to treatment, Treatment complications  
 Chief compliant-(reason for visit), Laterality, ocular symptoms in the current visit  
 Systemic evaluation 
 Ocular examination: Visual acuity, complete clinical ocular examination using slit-
lamp biomicroscopy, indirect ophthalmoscopy and Intraocular pressure 
 Relevant investigations 
 Final Laterality and course, Anatomical diagnosis, Etiological diagnosis, Treatment 
plan 
Data was analysed with IBM Inc. SPSS version 21  
Data pertaining to age, gender, location of uveitis, chronicity, and diagnosis were extracted 
and analysed in accordance with the International Uveitis Study Group (IUSG) 
recommendation,.(3) 
 
 
 
 
 Definitions  
Anterior uveitis is defined as the inflammation of the anterior chamber of the eye. It consists 
of iritis (inflammation of the iris), anterior cyclitis (inflammation of the anterior part of the 
ciliary body). (2) 
Intermediate uveitis is defined as inflammation with the vitreous as the major site of 
inflammation. The presence of peripheral vascular sheathing and/ or macular edema will not 
change the diagnosis of intermediate uveitis. 
Posterior uveitis is defined as the inflammation where the primary site of inflammation is the 
choroid or retina. It includes focal, multifocal or diffuse choroiditis, retinitis, retinochoroiditis, 
chorioretinitis and neuroretinitis. (2) 
Panuveitis is defined as the inflammation with no predominant site of inflammation but 
involves anterior chamber, vitreous and choroid. 
Definitions of uveitis according to the course of the disease 
Acute uveitis is defined as an episode of uveitis characterised by sudden onset and limited 
duration (less than or equal to three months).  
 Recurrent uveitis is defined as repeated episodes of uveitis separated by periods of inactivity 
with duration more than or equal to three months without treatment. 
Chronic uveitis is defined as persistent uveitis with relapse in less than three months after 
discontinuing treatment. 
Improvement in uveitis is defined as a two-step decrease in the level of inflammation or 
disease became inactive. 
Worsening in uveitis is defined as a two-step increase in the level of inflammation or an 
increase to maximum grade. 
Granulomatous uveitis is characterised by large mutton fat keratic precipitates. 
  Non-granulomatous uveitis is characterized by absence of large mutton fat keratic 
precipitates. Small keratic precipitates are seen. 
 
 
International Uveitis Study Group Etiological classification  
Infectious uveitis:  
 Bacterial   
 Viral  
 Fungal  
 Parasitic  
 Others 
Non-infectious uveitis: 
 Known systemic association  
 Not known systemic association (Idiopathic uveitis) 
Masquerade syndromes:  
 Neoplastic  
 Non-neoplastic 
 
  
 Revised Diagnostic criteria for Vogt-Koyanagi-Harada disease (International Committee 
of Nomenclature, 2000) (111) 
Complete Vogt-Koyanagi-Harada syndrome 
I. No history of penetrating ocular trauma or surgery 
II. No clinical or laboratory evidence of other ocular or systemic disease 
Ill. Bilateral ocular disease (either A or B below must be met): 
A. Early manifestations 
1. Diffuse choroiditis as manifested by either: 
a. Focal areas of subretinal fluid, or 
b. Bullous serous subretinal detachments 
2. With equivocal fundus findings, then both: 
a. Fluorescein angiography showing focal delayed choroidal perfusion, 
pinpoint leakage, large placoid areas of hyperfluorescence, pooling of 
dye within subretinal fluid, and optic nerve staining 
b. Ultrasonography showing diffuse choroidal thickening without 
evidence of posterior scleritis 
B. Late manifestations 
1. History suggestive of findings from IIIA. and either both 2 and 3 below, or 
multiple signs from 3 
2. Ocular depigmentation 
a. Sunset glow fundus, or b. Sugiura sign 
3. Other ocular signs 
a. Nummular chorioretinal depigmentation scars, or 
b. RPE clumping and/or migration, or 
c. Recurrent or chronic anterior uveitis 
 IV. Neurologic/auditory findings (may have resolved by time of examination): 
A. Meningismus 
B. Tinnitus 
C. Cerebrospinal fluid pleocytosis 
V. Integumentary findings (not preceding central nervous system or ocular disease) 
A. Alopecia 
B. Poliosis 
C. Vitiligo 
Incomplete Vogt-Koyanagi-Harada syndrome 
Criteria I to III and either IV or V from above 
Probable Vogt-Koyanagi-Harada syndrome 
Criteria I to III from above must be present 
Isolated ocular disease 
  
 International Criteria for the Diagnosis of Ocular Sarcoidosis: First International 
Workshop on Ocular Sarcoidosis (IWOS) 2009 (16) 
Intra ocular signs  
(1) Mutton-fat keratic precipitates (KPs)/small granulomatous KPs and/or  
Iris nodules (Koeppe/Busacca) 
(2) Trabecular meshwork (TM) nodules and/or  
Tent-shaped peripheral anterior synechiae (PAS)  
(3) Vitreous opacities displaying snowballs/strings of pearls  
(4) Multiple chorioretinal peripheral lesions (active and/or atrophic) 
(5) Nodular and/or segmental peri-phlebitis (± candlewax drippings) and/or  
Retinal macroaneurism in an inflamed eye  
(6) Optic disc nodule(s)/granuloma(s) and/or  
Solitary choroidal nodule  
(7) Bilaterality 
The laboratory investigations 
(1) Negative tuberculin skin test in a BCG-vaccinated patient or  
Negative in a patient having had a positive tuberculin skin test previously  
(2) Elevated serum angiotensin converting enzyme (ACE) levels and/or  
Elevated serum lysozyme  
(3) Chest x-ray revealing bilateral hilar lymphadenopathy (BHL)  
(4) Abnormal liver enzyme tests 
(5) Chest CT scan in patients with a negative chest x-ray result 
 
 
 
 In inpatients whom other possible causes of uveitis had been excluded 
 
TABLE-1  Level of certainty of having sarcoidosis 
1 Definite ocular sarcoidosis Biopsy-supported diagnosis  
With compatible uveitis 
2 Presumed ocular sarcoidosis Biopsy not done but 
Chest x-ray positive showing bilateral 
hilar lymphadenopathy 
With compatible uveitis 
3 Probable ocular sarcoidosis Biopsy not done  
Chest x-ray did not show bilateral hilar 
lymphadenopathy 
With at least 3 of the intraocular signs 
and 2 positive laboratory tests 
4 Possible ocular sarcoidosis Lung biopsy negative 
But at least 4 of the intraocular signs and 
2 positive laboratory investigations  
 
 
  
 TABLE -2 The International Criteria for Behcet’s Disease (ICBD) 2006 (112) 
 
 Clinical manifestations Score 
I Oral aphthosis (OA) 1 
II Genital aphthosis (GA). 2 
III Skin manifestations, 
Pseudofolliculitis (PF)  
Erythema nodosum (EN) 
1 
IV Ocular manifestations 
Anterior uveitis (AU)  
Posterior uveitis (PU) 
Retinal vasculitis (RV) 
2 
V Pathergy phenomenon (PP) 1 
VI Vascular manifestations (VMs) 
Superficial phlebitis 
Deep vein thrombosis 
Large vein thrombosis,  
Arterial thrombosis  
Aneurysm 
1 
. 
 A patient has to get three or more points to be diagnosed/classified as having 
Behcets’ disease. 
.  
 
. 
 DIAGNOSTIC CRITERIA FOR INTRAOCULAR TUBERCULOSIS (110,113) 
Clinical presentations with not associated with any other known clinical entity 
1. Granulomatous anterior uveitis  
2. Non-granulomatous anterior uveitis, not associated with any other known clinical entity  
3. Intermediate uveitis, with/without healed/active focal lesions  
4. Posterior uveitis, including subretinal abscess, choroidal/disc granuloma, multifocal 
choroiditis, retinal periphlebitis and multifocal serpiginous choroiditis  
5. Panuveitis 
6. Rarely, scleritis (anterior and posterior), interstitial and disciform keratitis. 
Diagnostic categories  
Presumptive ocular TB  
A patient with one of the clinical presentations and no association with any other known 
clinical entity 
Possible ocular TB (1, 2 and 3 together or 1 and 4)  
1. At least one clinical sign suggestive of ocular TB and other aetiologies excluded 
2. X-ray/CT chest not consistent with TB infection and no clinical evidence of extraocular 
TB 
3. At least one of the following: 
a. Documented exposure to TB 
b. Immunological evidence of TB infection 
4. Molecular evidence of Mycobacterium tuberculosis  infection. 
 
. 
 
 
 Probable ocular TB/Clinically diagnosed ocular TB (1, 2 and 3 together)  
1. At least one clinical sign suggestive of ocular TB and other aetiologies excluded 
2. At least one of the following 
a. Evidence of chest X-ray consistent with TB infection  
b. Clinical evidence of extraocular TB  
c. Microbiological confirmation from sputum or extraocular sites  
3. At least one of the following: 
a. Documented exposure to TB 
b. Immunological evidence of TB infection 
Bacteriologically confirmed ocular TB (1and 2 together) 
1. At least one clinical sign of ocular TB  
2. Confirmation of Mycobacterium tuberculosis  from ocular fluids/tissues 
a. Microbiological (smear/culture) or  
b. Histopathological 
Note: Extraocular TB disease is often absent in ocular TB patients, and patients do not usually 
have systemic symptoms of fever and weight loss. 
 
 
 
 
 
 
. 
 
 
 Vision assessment 
 Vision (Presenting distance visual acuity) was recorded with the use of Snellen’s chart 
at six metres and was categorized according to the revised World Health Organization 
Classification. 
TABLE-3 Classification Visual impairment including blindness (binocular or 
monocular).(114) 
Category Presenting distance visual acuity 
Worse than: Equal to or better than: 
0 Mild or no visual impairment 
 
6/18 
1 Moderate visual impairment 6/18 6/60 
2 Severe visual impairment 6/60 3/60 
3 Blindness 3/60 1/60 or Counting fingers 
(CF) at one metre 
4 Blindness 1/60 or Counting 
fingers (CF) at one 
metre 
Light perception 
5 Blindness No light perception 
9 Undetermined or unspecified 
 
 
 
. 
 
 
 TABLE -4 Visual impairment (binocular or monocular) 
Worse than Equal to or better than Category 
 6/12 No visual impairment        
6/12 6/18 Mild visual impairment       
6/18 6/60 Moderate visual impairment      
6/60 3/60 Severe visual impairment      
3/60  Blindness              
 
 
  
 RESULTS 
One hundred and four patients were recruited into our study from November 2015 to November 
2016. The patients presented to us from different parts of the country. The majority of the 
patients were from Tamil Nadu, especially Vellore.  
 
Age distribution 
The age of the patients in our study ranged from 3 to 87 years. The mean age was 38.75 years 
(SD – 16.049 years). 
Figure-1 Age Distribution 
 
 Gender Distribution 
There were 51 males (49%) and 53 females (51%) in the study. The age range in boys/men 
was 12-87 years and in girls/women was 3-66 years. 
 Figure-2 Gender Distribution 
 
Distribution of Occupation 
Of the 104 patients, 34 (32.7%) were housewives, 17 (16.3%) were students, 9 (8.7%) were 
coolie workers, 8(7.7%) were farmers. 
Figure-3 Distribution of Occupation  
 
 Figure-4 MAP OF INDIA with depicting the State of residence of the study patient 
 
76 patients (73.2%) were from Tamil Nadu. Of these 66 patients (86.8%) were from Vellore. 
12 patients (11.5%) were from West Bengal. 7 patients (6.8%) were from Andhra Pradesh 
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 Only 4 patients were able to recollect a positive family history of any connective tissue 
disorder. 
.  
 
Family History of Infectious disease  
Three patients had family history of exposure to tuberculosis. Two of these patients had 
systemic tuberculosis concurrent with the diagnosis of ocular disease. 
Figure-6 pulmonary tuberculosis 
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FIGURE-5
FAMILY HISTORY OF CONNECTIVE TISSUE 
DISORDER
Interstitial Lung disease
Unspecified connective tissue
with Uveitis
Psoriasis
Rheumatoid arthritis
 34 years old female with TB associated 
bilateral recurrent multifocal choroiditis. 
 46 years old female with TB associated 
chronic bilateral anterior uveitis. 
 24 years old male with idiopathic chronic 
non-granulomatous unilateral anterior uveitis 
 MEDICAL HISTORY OF SYSTEMIC ILLNESS 
Thirty two patients (31%) had history of systemic illness. Of these 32 patients, 17 patients 
(53%) had inflammatory joint related pathology.  
Figure-7 medical history of systemic illness   
 
 Figure -8 Associated systemic illness 
 
 
 
 Medical History of exposure to Infectious disease  
Twenty six patients (25%) had proven systemic diagnosis of infectious disease. 7 patients 
(6.7%) had tuberculosis, 5 patients (4.8%) had HIV. 
Figure -9&10 medical history of exposure to Infectious disease 
 
 
 History of Exposure to Animals 
Only 2 patients (1.9%) had history of exposure to animals.  
Animal Final diagnosis 
DOG      
Idiopathic bilateral recurrent anterior 
uveitis  
CAT        
Viral recurrent unilateral Uveitis 
    
. 
 
 
 
 
 
 
 
 
  
Ocular Injury 
Eight patients (7.7%) had ocular injury                   
Figure -11 Ocular Injury 
 
Four (3.8%) had closed globe injury, three (2.9%) had open globe injury and one (1%) had 
chemical injury.                                         
Figure -12 Type of injury 
 
Of the eight patients with ocular injury, 4 had uveitis in the same eye while the other four had 
injury to the opposite eye.      
Figure -13 Laterality and Type of injury 
 
  
Number of Episodes- Among the 104 patients, for 44 patients (42.3%) it was the first episode 
of uveitis while 60 patients (57.8%) had more than one episode. Of the patients with first 
episode, 21 (47.7%) were in 21-40 years age group and 11 (25%) were below the age of 20 
Figure -14 Number of Episodes 
 
More males presented with first episodes 
 
Figure-15 & 16 Gender and Age Distribution among patients with 1st Episodes of uveitis 
 
  
Laterality of Symptoms at Presentations 
At the onset of Uveitis 57 patients (54.8%) had unilateral eye symptoms, 43 patients (41.3%) 
had bilateral symptoms but at the current presentation 50% (n=52) had bilateral eye symptoms 
at presentation. 49 patients (47.1%) had unilateral eye symptoms and 3 patients (2.9) had 
alternating eye symptoms. 
 
Figure -17 Laterality of symptoms in primary presentation 
 
 
 
Figure -18 Laterality of symptoms in current presentation 
 
 
  
Comparison of symptoms in Initial and Current episodes 
Both at initial onset of uveitis and current presentations visual disturbance was the most 
common symptom followed by redness, pain, photophobia and watering respectively. Eighty 
one patients (77.9%) had visual disturbances at the first episode but this increased to 87.5%. 
by the time they arrived at the clinic. 
Figure -19 & 20 symptoms at presentations 
 
.Table-( ) Symptoms  At onset of uveitis n, (%) At current presentation 
of uveitis n, (%) 
Visual Disturbance  81 (77.9%) 91 (87.5%) 
Redness 62 (59.6% 60 (57.7%) 
Pain 48 (46.2%) 48 (46.2%) 
Photophobia  31 (29.8%) 34 (32.7%) 
Watering  19 (18.3%)   20 (19.2%) 
  
Type of Visual Disturbances 
 
 
Decrease in vision was the commonest among visual disturbances both at onset (n=63, 60.6%) 
and at current presentation (n=72, 69%). Next common symptoms were diffuse blurring of 
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Figure-21 Visual disturbances during primary episode
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Figure-22 Visual disturbances during current episode
 vision and floaters. 
Treatment History  
Out of 104 twenty three patients (22.1%) had no prior treatment for uveitis at presentation (first 
visit to eye care centre) Thirty nine patients (37.5%) were already on medication at the time of 
current presentation. Of these 82% (n=32) had anterior uveitis. 
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Figure-23 Treatment history at presentation
  
Treatment Compliance 
 Eighty one patients were on prior treatment and 54 patients (67%) gave history of good 
treatment compliance. 
 Figure-24 Treatment Compliance 
 
Treatment response 
Fifty patients (62%) showed improvement while 16 patients (20%) had no improvement of 
symptoms on treatment. Five patients (6%) worsened while still on treatment and 12% patients 
(n=10) worsened when they went off treatment. Of the 54 patients with good compliance, 82% 
patients (n=46) showed improvement on treatment while 11% patients (n=6) had no 
improvement and 3.7% (n=2) worsened on treatment. 
 
Figure -25 Treatment response 
 
  
Complications due to treatment were found in 37 patients (45.68%). Of these, 19 (51%) 
developed cataract and 18 (49%) showed steroid response. 
 
Figure -26 Treatment complications 
 
. 
Figure-27 Types of complications 
 
 
 
 
  
PRESENTING DISTANCE VISUAL ACUITY (according to laterality of disease) 
Forty two patients (40 %) had unilateral disease and 62 patients (60 %) had bilateral disease 
 
Figure-28 Affected eye vision in unilateral disease  
 
 
 
Figure-29 Better eye vision in bilateral disease 
 
 
 
 
  
Visual impairment  
Visual impairment was present in 33(31.73%) patients. Of these 33 patient, 24 patients had 
bilateral disease  
Figure-30 visual impairment  
 
 
 
 
Figure-31 Visual impairment based on Presenting distance visual acuity  
 
 
 
  
INTRAOCULAR PRESSURE 
On presentation 51.9% (n=54) patients had IOP within normal range while 19% (n=20) had 
low IOP and 14% (n=15) had high IOP. High IOP due to steroid response was found in 14% 
(n=15) patients 
Figure-32 Intraocular pressure 
 
. KERATIC PRECIPITATES 75 patients had evidence of KP of these 14(19%) had 
granulomatous KPs and 61 (81%) had non-granulomatous type  
 
Figure-33 Type of Keratic precipitates when present 
 
 
 COURSE OF UVEITIS 
Forty patients (38.5%) had acute uveitis, 34 patients (32.7%) had chronic uveitis while 30 
(28.8%) had recurrent uveitis. 
Figure-34 Course of uveitis 
 
 
Figure-35 Final Laterality 
 
 ANATOMICAL DIAGNOSIS OF UVEITIS 
Of the 104 patients in the study, anterior uveitis was found in 59 patients (56.7%), posterior 
uveitis in 21 patients (20.2%), panuveitis in 14 patients (13.5%) and intermediate uveitis in 8 
patients (7.7%). Scleritis was found in 2 patients (1.9%). Eighty three patients (80%) had 
anterior chamber inflammation irrespective of the anatomical diagnosis, of these, 20 patients 
(19%) were pure iridocyclitis.  
Figure-36 Anatomical diagnosis 
 
Among the 44 patients with first episode of uveitis, 43% had anterior uveitis, 34% had posterior 
uveitis, 18% had panuveitis and 4.5% had intermediate uveitis. 
 
Figure-37 Anatomical diagnosis in patients with first episode  
 
 
  
Course of uveitis in anatomic groups  
Figure-38 Course of uveitis  
 
 
 
Posterior uveitis  
Of the 21 patients with posterior uveitis, 8 patients (38%) had multifocal choroiditis. 
 
Figure-39 Types of Posterior uveitis 
 
 Vasculitis associated with uveitis 
In the study, out of 104 patients, 9 (8.7%) patients were found to have vasculitis associated 
with uveitis. Three patients had infectious uveitis - 2 patients had TB associated posterior 
uveitis and 1 patient had CMV retinitis. Four patients had non-infectious uveitis, one patient 
each with diagnosis of sarcoidosis, Behcet’s disease, VKH and Eales disease. 
Figure-40 Types of Vasculitis associated with uveitis 
 
 
SCLERITIS 
In the study, 7 (6.7%) patients had scleritis. Three patients had anterior scleritis of idiopathic 
origin. Two patients had posterior scleritis of idiopathic etiology and two had VKH related 
posterior scleritis. 
Figure -41 Types of scleritis associated with uveitis 
  
 
 Relevant Investigation to confirm diagnosis 
Twelve patients (11.5%) had positive relevant investigations to confirm the diagnosis of 
uveitis. Of these 7 patients had infectious etiology such as tuberculosis, leprosy, CMV and 
toxoplasmosis. 5 patients whose investigations positive were of non-infectious etiology such 
as HLA-B27, HLA-B51 and rheumatoid factor. 
 
Figure-42 Investigation 
 
 
 
 
 
 
 
 
 
 
 
 
 ETIOLOGICAL DIAGNOSIS 
Figure-43 Etiological diagnosis 
 
 
 
Figure-44 Etiological diagnosis in anatomical subgroups 
 
 In our study, (figures 43&4 44) 59 patients had anterior uveitis. Of these, 23 (39%) patients 
had idiopathic uveitis, 19 (32%) patients had infectious cause for uveitis and 17 (29%) patients 
had non-infectious cause for uveitis.  
Eight patients were diagnosed to have intermediate uveitis. Of these 7 had idiopathic uveitis 
and 1 had non-infectious cause for uveitis. 
Twenty one patients were diagnosed to have posterior uveitis. Of these, 13 (62%) patients had 
infectious cause for uveitis, 6 (29%) due to a non-infectious cause and 2 (9.5%) due to 
idiopathic etiology. 
Fourteen patients were diagnosed to have panuveitis. Of these, 8 cases were due to a non-
infectious cause, 4 due to idiopathic and 2 cases due to infectious etiology. 
 
DEFINITIVE ETIOLOGICAL DIAGNOSIS 
Infectious uveitis 
Of the 104 patients, 15 (14.4%) patients had viral cause for uveitis, 8 (7.7%) patients 
tuberculous associated and 5 (4.8%) patients had toxoplasmosis associated uveitis. 
 
Figure-45 Infectious uveitis 
 
 Non-infectious etiologies with known systemic associations  
In the study, among the non-infectious etiological factors, 9 % cases were due to VKH, 6 
(5.8%) HLA-B27 related, 5 (5%) JIA associated and 3(3%) sarcoidosis related uveitis. One 
patient had sympathetic ophthalmia. Four patients had connective tissue disorder related uveitis 
Figure-46 Non-infectious uveitis 
 
 
 
 
 Childhood uveitis 
Figure-47 Childhood uveitis 
 
There were 10 (9.6 %) children in the study ranging from 3 years to 16 years.  
Of these, 4 children had Juvenile Idiopathic Arthritis (JIA) associated anterior uveitis                                 
(2 unilateral and 2 bilateral). JIA patients did not have visual impairment in our study.  
Three children had idiopathic uveitis 
Three year old girl with unilateral acute anterior uveitis (affected eye visual acuity – 3/60) Six 
year old girl with unilateral acute pan uveitis (affected eye visual acuity – HM) 
Sixteen year old boy with bilateral chronic anterior uveitis and complicated cataract (visual 
acuity RE-6/24, LE-PL positive) 
HLA-B27 associated uveitis – One 15 year old boy with unilateral anterior uveitis. Patient did 
not have visual impairment (visual acuity – 6/6). 
Toxoplasma uveitis – One 16 years old girl with unilateral posterior uveitis with mild visual 
impairment (visual acuity – 6/18). 
Sarcoidosis associated uveitis – One 12 years old patient with bilateral posterior uveitis and 
moderate visual impairment (visual acuity both eyes – 6/36).  
 HLA-B27 associated anterior uveitis  
There were 6 patients diagnosed with HLA-B27 associated anterior uveitis. The course of 
uveitis was recurrent in 3 patients, acute in 2 and chronic in 1 patient. Four patients had 
unilateral involvement with no visual impairment and two patients had bilateral affection with 
one of them having mild visual impairment 
Figure-48 HLA-B27 associated anterior uveitis 
. 
Uveitis in patients with Tuberculosis 
There were 8 patients with tuberculosis associated uveitis in our study. Four of them had 
anterior uveitis and the other four had posterior uveitis. One of the patients with posterior 
uveitis had severe visual impairment (visual acuity in the affected eye – 1/60). 
Uveitis in patients with HIV infection 
There were 5 (4.8%) patients with HIV infection in this study group. Two patients had 
bilateral viral anterior uveitis and 3 had Cytomegalovirus (CMV) retinitis (two unilateral and 
one bilateral posterior uveitis).          Chart-49 Uveitis in patients with HIV infection
 
 Chart-50 Complications during the course of treatment 
 
Of the 104 patients, 54 of them developed complications of uveitis or the medication. 
Cataract was the most common complication 13 patients had developed cataract and 
another eight underwent cataract surgery. Other major complications were cystoid macular 
edema (14 patients) and secondary glaucoma (7 patients) 
 
  
 DISCUSSION 
The uvea constitutes the vascular coat of the eye and inflammation of this structure is 
broadly defined as uveitis. This disease can be broadly classified based on etiology, location 
and clinical course of the disease. Uveitis can be an entity on its own involving only one eye 
or both eyes or a manifestation of a systemic disease. (115) 
The pathogenesis of uveitis is multifactorial and involves different inflammatory 
pathways and defects in the regulatory mechanisms of the immune system. Corticosteroids is 
the cornerstone drug in the management of uveitis. (116) but with the increasing knowledge of 
the pathogenesis of the immune system, targeted biologic therapies are being developed. (117)  
Uveitis is currently reported to be the third leading cause of blindness worldwide. It 
currently accounts for 10% of preventable vision loss in the United States and 15% worldwide. 
(23,118) Factors affecting the development of uveitis widely vary across the world due to 
environmental changes like climate, topography and geography, socioeconomic differences in 
the population, cultural differences and professional differences. A large series from south 
India reported their experience over 6 years and compared it to reports from around the world. 
In their hospital based data, uveitis was seen in 0.8% of the patients. The common confirmed 
etiological diagnoses among infectious causes were leptospirosis, tuberculosis and herpes 
related disease in adults and parasitic uveitis in children. (107)  
The age of patients in our study ranged from 3 to 87 years. The majority of the patients 
in the study ranged in the age group from 31-40 years (29%) followed by 41-50 years (20%) 
and 51-60 years (16%) which is similar to multiple published studies. (5,6,41)  Gupta A et al 
in a retrospective study done north India from 1996-2001 reported ages ranging from 1.5 years 
to 75 years with mean age of 34.4 years. Das D et al in study done North east India showed a 
 range of 2 to 61 years.  Yang P in Chinese study in 2005 reported mean age at presentation as 
33.8 +/- 16.5 years. (119) 
Gender distribution was almost equal in our study, 51% females and 49% in males. 
Pacific Ocular inflammation study (27) had shown that there was no difference in the incident 
rates between males and females. With few exception, most of the surveys from developed 
countries reported equal gender distribution or a slight predominance of women. Merrill PT et 
al reported a female to male ratio of 1.6:1 referral population with a high percentage of African 
Americans.(120) In a recent study by Luca C et al showed female to male ratio of 1.44:1 among 
uveitis patients from northern Italy.(121) Male predominance is noted in studies from 
developing countries including India. Female to male ratio 1:2 reported from Northeast India, 
to almost 1:3 from south India.(6,28,41,107) Factors contributing to such differences that are 
mentioned are complex and the most common being the fact that in developing countries  males 
may have more access to care and adequate medical treatment if they are ill (122). Our gender 
distribution contrary to the trend in south India might be due to better access health care.  
Family history of connective tissue disorders was positive in 3.8% patients.  Of these, 
one patients with HLA B-27 uveitis had family history of unspecified connective tissue and 
uveitis while another patient had family history of Psoriasis. Most forms of non-infectious 
uveitis occur within families and are polygenic with complex inheritance patterns. Many are 
found to occur in families in which clustering of other autoimmune diseases have been 
observed. Almost all polygenic diseases have a HLA genetic association. Some association can 
be strong as in HLA-A29 with birdshot chorioretinopathy and HLA-B27 with Acute anterior 
uveitis. However majority of people with positive markers do not develop Uveitis also (123–
127) 
 
 Visual disturbance (87.5%) was the most common symptom of uveitis followed by 
redness, pain, photophobia and watering respectively. Patients presented with blindness in 
4.5% patients and 20% patients had moderate to severe visual impairment in the first episode. 
Twenty five percent of the blindness in developing countries has been attributed to uveitis. (19) 
 Bilateral eye involvement was found in 75% of non-infectious disease and 55% of 
idiopathic cases. Systematic review by Rathinam et al showed that in overall rates unilateral 
and bilateral diseases are similar but non-infectious/auto immune entities tends to affect both 
the eyes (107) 
Anterior uveitis was the commonest uveitis (56.7%) in our study. Our study had a 
higher percentage of anterior uveitis cases compared to other studies done in India (39-49%) 
and other Asian studies (28-50%).(5,6,29)  Acute unilateral non-granulomatous uveitis 
occurred more frequently. Uveitis due to infectious etiologies were present in 33% of study 
patients. Majority of the cases did not have any known systemic association or infection 
(idiopathic, 37%). These findings are similar to the data from studies done by Rathinam et al 
(28) from south India in the same state as our centre. However, in a prospective study conducted 
in North Indian referral centre from 2011-2013 by Venkatesh, et al, they found that, out of 980 
patients, 42% patients had anterior uveitis and majority due to idiopathic cause.(26) 
There were total of 59 cases with anterior uveitis. Idiopathic anterior uveitis was seen 
in 39% of the patients. This was the commonest followed by viral (20%), HLA-B27 (10%) and 
TB (7%). Kalpana Babu, et al reported clinical profile of polymerase chain reaction proven 
viral anterior uveitis. Out of 36 patients, 24 patients had Varicella Zoster, 7 had HSV,3 CMV 
and 2 Chikungunya. Increase in IOP was seen in 28% of cases. Recurrence was seen in 61% 
cases. (4) 
 Idiopathic etiology accounted for majority of patients with anterior uveitis (39%) and 
intermediate uveitis (88%), Only 28.6% of panuveitis and 9.5% cases of posterior uveitis were 
idiopathic. while infectious caused 62% of posterior uveitis, 32% of anterior uveitis and 14% 
of panuveitis. Non-infectious etiologies with known systemic association were the largest 
etiological group in panuveitis (57%). Non-infectious etiologies caused 29% of anterior 
uveitis,12.5% of intermediate uveitis and 29% of posterior uveitis   
Isolated intermediate uveitis accounted for only 7.7% cases of all the patients in our 
study. Seven patients had no identifiable cause and one was diagnosed to have Behcet’s 
disease. From reports around the world, rates of intermediate uveitis, ranges from 1.4-22%. 
Studies in India, found intermediate uveitis in the range of 9.5-17.4% among uveitis patients. 
(6,26,28) From systematic reviews around the world, 60-100% intermediate uveitis was found 
to be idiopathic. (29) 
Twenty-one patients (20%) were diagnosed with posterior uveitis in our study. The 
commonest identifiable causes for the inflammation were toxoplasmosis (24%), tuberculosis 
(19%) and CMV (14%). In 10% of the cases no cause could be identified 
Panuveitis was seen in 13.5% of the patients in our study. Among those diagnosed with 
panuveitis, more than 70% had a specific etiology and 29% had no identifiable cause. Those 
with specific diagnoses were as follows - VKH (50%), viral (14%) and sympathetic ophthalmia 
(7%). Though worldwide, idiopathic uveitis is the most common cause of panuveitis, we found 
that 50% of the patients with panuveitis had VKH in our study profile, as compared to 45% 
reported by Das et al from hospital based study in North-east India. (128)   
 Infectious pathology was detected in 32.7% of patients in our study. Common etiology 
spectrum included viral uveitis (14%), tuberculosis (7.7%), toxoplasma (4.8%), CMV (2.9%) 
and syphilis (1.9%).  
 Among patients with uveitis of non-infectious etiology, 43% had systemic association. 
In our study, the spectrum of systemic diseases included Vogt-Koyanagi Harada disease, HLA-
B27 related, sarcoidosis, Juvenile idiopathic arthritis, Behcet’s disease, HLA-B51 related, 
Rheumatoid arthritis, Spondyloarthropathy, Reiter’s and undifferentiated connective tissue 
disorder related. A recent study reported by Gaurav Mathur, et al (1) reported that in non-
infectious anterior uveitis patients, 33% had HLA-B27 positive, 14% had spondyloarthropathy.  
Based on the frequency of presentation, patients with non-infectious and idiopathic 
uveitis had multiple episodes of uveitis. Recurrence rates was highest in those with idiopathic 
(68%) etiology. They were also seen in non-infectious etiology (56%) and infectious etiology 
(47%). The recurrence rates for were highest in HLA-B27 related disease (83%), followed by 
VKH (56%), viral (47%) and tuberculosis (72%). In those with chronic uveitis, idiopathic 
(32%) etiology was the commonest cause of recurrence, followed by TB (12%), viral (9%) and 
VKH (9%). 
High Intraocular pressure was found in 15 patients in our study. Seven patients out of 
12 patients with anterior uveitis of viral etiology had high IOP. In a review by Uwe Pleyer et 
al that Herpes simplex virus anterior uveitis caused raised intraocular pressure (IOP) in 38%–
90% of eyes. While with Herpes VZV IOP was elevated in 40–75% of cases. In acute CMV 
anterior uveitis, mean presenting IOP was 50 mmHg, The IOP may be elevated in Chronic 
CMV anterior uveitis but is not as high as that in the acute disease (129) 
 Relevant investigations were positive in 16% patients which included HLA-B27 
associated uveitis and JIA associated uveitis.  Some diseases were diagnosed with specific 
diagnostic criteria and therefore did not require extensive investigations.  
Childhood uveitis accounted for 9.6 % of cases in our study. The commonest cause was 
juvenile idiopathic arthritis related uveitis and was seen in 4 children. Three children had 
idiopathic uveitis, one case each of HLA-B27 associated uveitis, sarcoidosis and toxoplasmosis 
constituted the other three patients. In our study, anterior uveitis was the commonest (78%) 
among children. Acute uveitis was seen in 7 patients while 3 children had chronic uveitis and 
one with recurrent disease. Mild visual impairment was found in one patient and two of them 
had moderate visual impairment. Anju Gupta, et al (18) reported that childhood uveitis 
accounted for 5-10% of all uveitis and that anterior uveitis was the commonest. Common 
etiologies of childhood uveitis were reported as JIA (11.6-30%), idiopathic, viral and 
toxoplasmosis. JIA is the commonest cause of anterior uveitis in children. (18,130,131)  
Systemic steroid was used for treatment in 27% cases of uveitis. Immunomodulators 
along with topical and systemic steroids were used in 29% patients. Immunomodulators were 
prescribed in 22.5% acute cases, 38% chronic cases and 43.4% recurrent cases of uveitis.  
Corticosteroids are the mainstay of treatment in uveitis. Immunosuppressives have 
revolutionized treatment of recurrent and chronic uveitis. More targeted treatment options 
should be available in future as we get a better understanding of immunology and uveitic 
diseases. 
Of the 104 patients, 54 of them developed complications at presentation and or during 
the course of uveitis treatment. Complicated cataract was seen in 38% cases. Eight patients 
needed cataract surgery. Other complications included:  cystoid macular edema (CME)-(25%), 
 secondary glaucoma (13%), retinal detachment (5%), steroid response (7%) and band shaped 
keratopathy (4%). 
Epidemiological and etiological patterns of uveitis in different regions of the world 
have shown that there are similarities and differences in the pattern of uveitis influenced by 
geographical, environmental and genetic patterns. 
Most literature on hospital based uveitis profile studies which considered the full 
spectrum of uveitic cases, occurred before standardization of uveitis nomenclature in 2005. 
Many of them did not state the criteria that were used to diagnose uveitis. Hence, comparing 
the results becomes difficult. Multiple etiologies are associated with uveitis. A meticulous 
history taking, clinical examination, investigation would help in the diagnosis of the type and 
severity of uveitis. Early initiation of treatment, compliance and regular follow-up is essential 
to inhibit the progression of disease and relief of symptoms, thereby reducing the morbidity 
associated with uveitis. The management of uveitis is usually a team work involving 
ophthalmologists, rheumatologists and infectious disease specialists. 
  
 LIMITATIONS OF THE STUDY 
1. While there is no ambiguity in the diagnosis of active uveitis, diagnosis of inactive and past 
uveitis on the basis of history and clinical examination is not so easy especially when there 
are no associated systemic signs and symptoms at presentation. 
2. History suggestive of past uveitis elicited from a patient, may be very subjective, as ocular 
pain, discomfort and redness may be present in many ocular conditions other than uveitis. 
3. There is a high chance recall bias in family and past history.  
4. The missing information, if not distributed randomly, we will miss significant risk factors. 
5. The study is subject to confounding factors. Other risk factors may be present that were not 
studied.  
6. We can only determine the association and not the causation of all patients with uveitis in 
view of the expensive tests and unavailability of all tests. 
 
 
 
 
 
 
 
 
 CONCLUSIONS 
 The age group of 31 – 40 years had the highest prevalence of uveitis. Thus, uveitis may 
have a strong socioeconomic and quality of life impact because it often affects younger 
working-age patients 
 Gender distribution was almost equal in our study. 
 Visual disturbance was the most common symptom of uveitis  
 Family history of connective tissue disorders was positive in 3.8% patients 
 History of systemic tuberculosis was elicited in 2.9% patients. 
 Systemic illness caused uveitis in 43% of patients with non-infectious etiology. 
 Patients with non-infectious and idiopathic uveitis had a higher recurrence rate of 
inflammatory episodes.  
 In patients with chronic uveitis idiopathic cause was the commonest 
 Bilateral eye involvement was found in 75% of non-infectious disease and 55% of 
idiopathic cases. 
 Idiopathic etiology accounted for majority of anterior and intermediate uveitis while 
infectious etiology (62%) dominated the posterior uveitis group. 
 Idiopathic anterior uveitis was the commonest of all presentations. Viral uveitis was the 
commonest cause of infectious anterior uveitis 
 Toxoplasmosis and tuberculosis were the commonest cause of posterior uveitis  
 Vogt Koyanagi Harada disease was the commonest cause of panuveitis. 
 Childhood uveitis accounted for 7.6%of all uveitis cases. Commonest cause was Juvenile 
idiopathic arthritis related uveitis.  
 Viral etiology was the commonest cause of those patients with a high intraocular pressure 
during the episode of uveitis. 
  HLA-B27 was the commonest positive investigation in the non-infectious uveitis group. 
 Systemic steroid was used for treatment in 27% cases of uveitis.  
 Immunomodulators along with topical and systemic steroids were used in 29% patients. 
 Immunomodulators were prescribed in 22.5% acute cases, 38% chronic cases and 43.4% 
recurrent cases of uveitis. 
 Of the 104 patients, 54 of them developed complications of uveitis or the medication. 
Complicated cataract was the most common complication. 
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ANNEXURES 
 
 ANNEXURE-I  IRB APPROVAL   
 
  
  
  
 ANNEXURE II      
   CLINICAL RESEARCH FORM: UVEITIS PROFILE STUDY 
Serial no____    Schell hosp No: ___________________      CMC Hosp No:_________________                        
Name _______________ Age___year(s)   
Occupation______________Residence_____________                                      
Family history 
Connective tissue disorder Y / N /NA _______________________________ 
Exposure to infection          Y / N / NA ______________________________ 
Medical history 
Systemic illness                            Y / N    ____________________________ 
Exposure to infection                   Y / N     ____________________________ 
Exposure to animals                     Y / N     ____________________________ 
Ocular history  
Number of episodes ______ 
Primary symptom at presentation  
Laterality – Unilateral/ Right / Left/ Bilateral/ Alternating 
(RE)        Redness / Pain / Photophobia / Epiphora / Visual disturbances 
(LE)        Redness / Pain / Photophobia / Epiphora / Visual disturbances 
Visual disturbances: Decreased vision / Diffuse blur/ Scotomata (central / Peripheral)  
Floaters / Metamorphopsia / Micropsia / Macropsia. 
Chief complaint, reason for visit 
Laterality – Unilateral/ Right / Left/ Bilateral/ Alternating 
(RE)       Redness / Pain / Photophobia / Epiphora / Visual disturbances 
(LE)        Redness / Pain / Photophobia / Epiphora / Visual disturbances 
Visual disturbances: Decreased vision / Diffuse blur/ Scotomata (central / Peripheral)  
Floaters / Metamorphopsia / Micropsia / Macropsia. 
 Associated symptoms_______________________________________ 
Ocualar injury  (Y / N )      Right______________ Left ____________ 
Treatment history 
Topical medication /  
Topical + Systemic / 
 Topical +Systemic + Immunomodulators/  
Antibiotics/ ATT/ Acyclovir  
Compliance of the patient: GOOD/ POOR     
Response to treatment:  
 Improvement / No improvement /  
Worsened on treatment/  Worsened off treatment. 
Treatment complications: Y / N   Steroid response/ Cataract/ Others___________________ 
Systemic evaluation 
Skin _______________________                            CVS ________________________ 
RS  ________________________                           CNS_________________________ 
Joints ______________________                            Fever  ( Y / N )                        
Hearing loss ( Y / N ) 
Lymphadenopathy ( Y / N ) 
Ocular examination        
Visual acuity:          Right eye _________    Left eye_______ 
Scleritis Y / N  (Anterior / Posterior )     
Anterior uveitis ( Y / N  )   (With spillover / Without spill over)   
Granulomatous / Non granulomatous  
Intraocular pressure:  Low /Normal/ High / Steroid Response  
Acute/ Chronic / Recurrent              Unilateral/ Unilateral alternating / Bilateral 
 
 Anatomical diagnosis 
Anterior uveitis Iritis / Iridocyclitis/ Anterior cyclitis 
Intermediate uveitis Pars planitis /Posterior cyclitis / Hyalitis 
Posterior uveitis Focal /multifocal / diffuse Choroiditis 
Chorioretinitis /Retinochoroiditis /RetinitisNeuroretinitis 
Panuveitis  
 
Vasculitis: (Y / N ):  Systemic non infectious / Infectious / Ocular disorder   
Etiological diagnosis/ differential diagnosis:      Infectious / Non Infectious / Idiopathic  
 
Relevant investigations: (positive/negative) 
 
 
Definitive diagnosis 
 
  
Final Treatment :   
Topical steroids  / 
Topical and systemic steroids / 
Topical and systemic steroids  + immunomodulators/  
Antibiotics / ATT /       
 ANNEXURE-III  DATA SPREAD SHEETS 
 
  
 
